What is the appropriate dosing and administration protocol for terlipressin injection in patients with chronic liver disease?

Terlipressin Administration in Chronic Liver Disease with HRS-AKI

Start terlipressin at 1 mg IV bolus every 6 hours through a peripheral line, without requiring ICU admission or central venous access, and increase to 2 mg every 6 hours on day 4 if serum creatinine fails to decrease by at least 30% from baseline. 1

Dosing Protocol

Initial Dosing

• Starting dose: 1 mg IV bolus every 6 hours (administered over 2 minutes)
• Route: Peripheral IV line (no central line required)
• Setting: Does not require ICU monitoring 1

Dose Escalation

• Day 4 assessment: If serum creatinine decreases <30% from baseline, increase to 2 mg every 6 hours
• Discontinuation criteria: If serum creatinine remains at or above baseline on day 4, stop treatment 1
• Maximum duration: Up to 14 days
• Early discontinuation: Can stop 24 hours after creatinine decreases to <1.5 mg/dL 1

Alternative Administration Method

Continuous infusion (starting at 2 mg/day, increased every 24-48 hours up to 12 mg/day) shows lower complication rates with similar efficacy compared to bolus dosing 1, 2. This method requires lower total daily doses (mean 2.23 mg/day vs 3.51 mg/day for bolus) and has fewer adverse events (35% vs 62%) 2.

Concurrent Albumin Administration

• Day 1: 1 g/kg (maximum 100 g)
• Subsequent days: 20-40 g/day based on volume status 1
• Duration: Reassess need after 1-2 days; avoid excessive albumin to prevent respiratory failure 1
• Monitoring: Use point-of-care ultrasonography to guide volume status 1

Patient Selection Criteria

Appropriate Candidates

• Serum creatinine ≥2.25 mg/dL after 48 hours of volume expansion with albumin
• Creatinine <5 mg/dL (patients above this threshold have low response rates) 1
• SpO2 ≥90% 1

Absolute Contraindications

• SpO2 <90% 1
• Active coronary, peripheral, or mesenteric ischemia 1
• Known significant vascular disease 1

Use with Extreme Caution

• ACLF grade 3: High risk of respiratory failure; requires ICU monitoring if used 1
• MELD ≥35: Benefits may not outweigh risks 1
• Serum creatinine >5 mg/dL: Unlikely to benefit 1

Monitoring Requirements

Standard Monitoring (ACLF grade <3)

• Vital signs including pulse oximetry every 2-4 hours 1
• Daily serum creatinine
• Volume status assessment

Enhanced Monitoring (ACLF grade 3)

• ICU setting with continuous pulse oximetry 1
• Close hemodynamic monitoring

Common Pitfalls and Safety Considerations

Respiratory Failure Risk

The CONFIRM trial showed increased respiratory failure (14% vs 5% placebo) and death from respiratory failure (11% vs 2% placebo) 1. This risk is primarily driven by excessive albumin administration and increased cardiac afterload, not by terlipressin itself. Use judicious albumin dosing and avoid volume overload 1.

Ischemic Complications

Monitor for abdominal pain, digital ischemia, or cardiac ischemia. These are usually not severe and improve with dose reduction or discontinuation 3.

Response Assessment

• Insufficient response: <30% decrease in creatinine by day 4 warrants dose escalation 1
• No response: Creatinine at or above baseline on day 4 indicates treatment failure; discontinue 1
• Success: Two consecutive creatinine values ≤1.5 mg/dL at least 2 hours apart 4

Evidence Quality Note

The FDA approval is based on the CONFIRM trial, which demonstrated 29.1% HRS reversal with terlipressin versus 15.8% with placebo (p=0.012) 4. The 2024 AGA guidelines designate terlipressin as the vasoactive drug of choice for HRS-AKI 1. Recent evidence increasingly favors continuous infusion over bolus dosing for improved tolerability 2, 5, 6.